189 related articles for article (PubMed ID: 33216370)
21. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Gill H; Leung GM; Lopes D; Kwong YL
Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
[No Abstract] [Full Text] [Related]
22. Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
Rodgers GM; Kurtti AL; Gilreath JA
Am J Hematol; 2019 Mar; 94(3):394-395. PubMed ID: 30033660
[No Abstract] [Full Text] [Related]
23. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
Guan Y; Hasipek M; Jiang D; Tiwari AD; Grabowski DR; Pagliuca S; Kongkiatkamon S; Patel B; Singh S; Parker Y; LaFramboise T; Lindner D; Sekeres MA; Mian OY; Saunthararajah Y; Maciejewski JP; Jha BK
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35085104
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.
Bart-Smith EE; Kordasti S; Kulasekararaj AG; Richardson D; Mufti GJ; Marsh JC
AIDS; 2014 Nov; 28(18):2786-8. PubMed ID: 25333665
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
26. Deficient proliferation of myeloid, erythroid, and multipotent progenitor cells in long-term marrow cultures from patients with aplastic anemia treated with immunosuppressive therapy.
Gómez-Morales E; Martinez-Jaramillo G; Sánchez-Valle E; Valencia-Plata I; Arana-Trejo RM; Castro MA; Pizzuto-Chávez J; Mayani H
Am J Hematol; 1998 Oct; 59(2):149-55. PubMed ID: 9766800
[TBL] [Abstract][Full Text] [Related]
27. An Eltrombopag Red (Plasma) Alert.
Al-Samkari H; Goodarzi K
Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
[TBL] [Abstract][Full Text] [Related]
29. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
[TBL] [Abstract][Full Text] [Related]
30. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
31. [Thrombopoietin receptor agonist arouses new hope].
Häckel A
MMW Fortschr Med; 2016 Apr; 158(7):73. PubMed ID: 27071600
[No Abstract] [Full Text] [Related]
32. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
[TBL] [Abstract][Full Text] [Related]
33. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
Yuan FF; Zhang QL; Zhang LN; Xiong YY; Li MJ; Zhou H; Wei XD; Liu XJ; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):1021-1024. PubMed ID: 35045674
[No Abstract] [Full Text] [Related]
35. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
[No Abstract] [Full Text] [Related]
36. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
37. Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia.
Kelly D; Lamb V; Juvet F
J Vet Intern Med; 2020 Mar; 34(2):890-892. PubMed ID: 32096575
[TBL] [Abstract][Full Text] [Related]
38. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
[TBL] [Abstract][Full Text] [Related]
40. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
